"We at MSD believe that the government may consider recognizing the need to invest more in innovative medicines."
In Conversation
"In our region, we follow the global footprint quite closely with reproductive medicine and women’s health as our strongest therapy areas, followed by gastroenterology and urology."
"We expect that the significant investment and big engagements we have made in recent years in bringing new technologies to the Serbian health sector will start…
"The local requirements for national registration of a drug in Serbia, since Serbia is not part of the EU thus the centralized registration does not apply,…
"In Serbia, in certain cases, if you have a locally registered legal entity, you have to have an insurance policy issued by a local insurance company."
"One of our strategic plan for the coming years is to level a large part of our product portfolio with EU standards and fill in the…
"Since 2014, we have already united 69 member companies which shows that there is clear interest in building relationships in this community and seeking out other…
"The Serbian market is a generic-dominated market, with the local manufacturers still enjoying a privileged status."
"We, in the foundation, are trying to implement the sustainability philosophy in our daily work and implement the projects which can improve people’s health and preserve…
"We are a biotechnological and biopharmaceutical company, specializing in finding and providing new molecules and solutions for the unmet needs of patients across the region."
"We have seen massive growth since or foundation: from two to 75 employees currently, and we have further expanded our service offering."
"This region has a lot of potential, and this is the reason we are not only staying here but growing and developing, aiming to offer a…
